AS Brett
Abstract
A relatively new class of drugs inhibits HIV-1 protease, which is required for the production of infectious HIV particles. These two studies -- one from Europe and Australia, and the other from the U.S. -- examined the short-term effects of the HIV-1 protease inhibitor ritonavir. The two studies …
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
A relatively new class of drugs inhibits HIV-1 protease, which is required for the production of infectious HIV particles. These two studies -- one from Europe and Australia, and the other from the U.S. -- examined the short-term effects of the HIV-1 protease inhibitor ritonavir. The two studies …
Key concepts: Ritonavir, Protease inhibitor (pharmacology), Protease, Medicine, Virology, Human immunodeficiency virus (HIV), HIV-1 protease, Pharmacology